TLR2 and urinary bladder cancer: Synergistic immune activation with two chemical molecules: Poly(I:C)—a TLR3 targeted agent—and TLR2/4 inducer-BCG led to tumor suppression and the generation of a long-lasting protective immunity in the MBT-2 murine high-grade bladder cancer model [36].